Cabaletta Bio Inc (OQ:CABA)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 2929 Arch St Ste 600
Tel: N/A
IR: See website
Key People
Steven Nichtberger
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Anup Marda
Chief Financial Officer
Gwendolyn Knowlton Binder-Scholl
Executive Vice President, Science & Technology
J. Brian Stalter
General Counsel
David J. Chang
Chief Medical Officer
Business Overview
Cabaletta Bio Inc. is a clinical stage biotechnology company. The Company is focused on discovery and development of engineered T-cell therapies for B cell-mediated autoimmune diseases. The T cells are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. The Company's lead CAAR T cell product candidate are designed based on chimeric antigen receptor, and its T cell technology has been developed and is marketed for the treatment of B cell cancers. The Company has discovered and developed four product candidates, including its lead product candidate, to potentially treat patients with mucosal pemphigus vulgaris (mPV), and three additional product candidates that have demonstrated specific and selective target engagement in vitro. Its product pipelines include DSG3-CAART, DSG3/1-CAART, Musk-CAART and FVIII-CAART.
Financial Overview
For the six months ended 30 June 2020, Cabaletta BioInc revenues was not reported. Net loss applicable tocommon stockholders increased 28% to $15.6M. Higher netloss reflects Research and development increase of 87% to$9M (expense), General and administrative increase from$2.1M to $5.1M (expense), Stock-based Compensation in SGAincrease from $315K to $1M (expense).
Employees: 31 as of Jun 30, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $164.35M as of Jun 30, 2020
Annual revenue (TTM): $0.00M as of Jun 30, 2020
EBITDA (TTM): -$26.74M as of Jun 30, 2020
Net annual income (TTM): -$25.69M as of Jun 30, 2020
Free cash flow (TTM): -$23.09M as of Jun 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 24,039,594 as of Jul 29, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.